# macular edema FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/macular-edema

> No upcoming FDA catalysts in macular edema; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | completed, complete response letter | "•The Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| Nov 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | scheduled | "There is also an sBLA under review by the FDA for EYLEA HD every-four-week dosing and for the treatment of macular edema following retinal vein occlusion (RVO), which has a target action date in late November 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| November 2026 | [KIO-104 primary completion](https://sec-api.dev/pdufa/kio-104) | KPRX | Macular Edema | scheduled | "NCT06825702 (Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Kiora Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06825702)) |
| Nov 2026 to Feb 2027 | [KIO-104 topline data readout](https://sec-api.dev/pdufa/kio-104) | KPRX | Macular Edema | scheduled | "NCT06825702 (Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Kiora Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06825702)) |

## Drugs

- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [KIO-104](https://sec-api.dev/pdufa/kio-104) (KPRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/macular-edema.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "macular edema FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/macular-edema

```bibtex
@misc{secapidev_indications_macular_edema_20261116,
  title        = {macular edema FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/macular-edema}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_macular_edema_20261116","title":"macular edema FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/macular-edema","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
